Dateline City:
WHITEHOUSE STATION, N.J.
WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada,
today announced that researchers will present new data analyses of the
safety and efficacy of the companys investigational allergy
immunotherapy tablets (AITs) for ragweed pollen (Ambrosia
artemisiifolia) and grass pollen (Phleum pratense) at the
2013 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual
Meeting. The meeting will be held in San Antonio from February 22-26.
Language:
English
Contact HTML:
MerckMedia:Pam Eisele, 908-423-5042orLesley Brown, 267-305-3545orInvestor:Carol Ferguson, 908-423-4465orJustin Holko, 908-423-5088
Ticker Slug:
Ticker: MRK Exchange: NYSE
read more